Cogent Biosciences Inc (COGT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.97B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cogent Biosciences Inc (COGT) Stock Forecast
Analysts expect Cogent Biosciences (COGT) to earn -$2.33 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.43M. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 9 | 75.0% |
| Hold | 1 | 8.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 5142.4%.
- Fiscal year ending Dec 31, 2026
- -$2.33
- EPS consensus, revenue $5.43M
- Fiscal year ending Dec 31, 2027
- -$1.29
- EPS consensus, revenue $284.66M
- Next report
- Feb 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.33 | -$2.53 to -$2.02 | 9 | $5.43M | N/A | 9 |
| Dec 31, 2027 | -$1.29 | -$2.02 to -$0.45 | 9 | $284.66M | $121.83M to $393.00M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.64 for the quarter ending Dec 31, 2026 to -$0.53 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.64 | -$0.72 to -$0.55 | 13 | $5.55M | N/A | 13 |
| Mar 31, 2027 | -$0.53 | -$0.56 to -$0.51 | 3 | $29.19M | $7.20M to $41.00M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.21.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.33 | -$2.22 | -$2.21 | -$2.21 | -$2.21 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.29 | -$1.20 | -$1.11 | -$1.09 | -$1.13 | N/A |
| Quarter ending Mar 31, 2027 | -$0.53 | -$0.52 | -$0.52 | -$0.51 | -$0.44 | N/A |
Frequently Asked Questions About COGT
What is the COGT stock forecast?
Consensus analyst estimates put Cogent Biosciences's EPS at -$2.33 for the fiscal year ending Dec 31, 2026, on revenue of $5.43M. The consensus rating from 12 analysts is Buy.
How do analysts rate COGT stock?
Of 12 analysts covering Cogent Biosciences, 2 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from COGT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.33, with estimates from -$2.53 to -$2.02 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.29, with estimates from -$2.02 to -$0.45 from 9 analysts.
What revenue do analysts expect from Cogent Biosciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.43M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $284.66M, with estimates from $121.83M to $393.00M.
How many analysts cover COGT?
12 analysts rate Cogent Biosciences stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
COGT pages: Overview, Earnings, Forecast, Financials, Competitors